Russell Investments Group Ltd. grew its holdings in Intersect ENT, Inc. (NASDAQ:XENT) by 8.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,214 shares of the medical equipment provider’s stock after purchasing an additional 3,090 shares during the period. Russell Investments Group Ltd. owned approximately 0.13% of Intersect ENT worth $1,068,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Intersect ENT by 0.4% in the first quarter. Wellington Management Group LLP now owns 2,921,012 shares of the medical equipment provider’s stock valued at $50,095,000 after purchasing an additional 10,683 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Intersect ENT by 4.8% in the first quarter. Morgan Stanley now owns 602,499 shares of the medical equipment provider’s stock valued at $10,333,000 after purchasing an additional 27,550 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Intersect ENT by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 59,774 shares of the medical equipment provider’s stock valued at $723,000 after purchasing an additional 206 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Intersect ENT in the first quarter valued at $590,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Intersect ENT in the first quarter valued at $590,000. Institutional investors own 83.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/13/intersect-ent-inc-xent-shares-bought-by-russell-investments-group-ltd.html.

Intersect ENT, Inc. (XENT) traded down 0.65% during midday trading on Wednesday, reaching $30.80. 80,716 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $30.17 and a 200 day moving average price of $23.87. Intersect ENT, Inc. has a 52 week low of $7.65 and a 52 week high of $33.25. The company’s market cap is $899.02 million.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The firm had revenue of $24.00 million for the quarter, compared to analyst estimates of $22.62 million. During the same period in the previous year, the business earned ($0.21) EPS. The company’s revenue was up 24.4% compared to the same quarter last year. Analysts anticipate that Intersect ENT, Inc. will post ($0.61) EPS for the current year.

A number of analysts have recently issued reports on XENT shares. BidaskClub lowered Intersect ENT from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Canaccord Genuity restated a “buy” rating and issued a $32.00 target price on shares of Intersect ENT in a report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price target on shares of Intersect ENT and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Bank of America Corporation upped their price target on shares of Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $35.00 price target on shares of Intersect ENT in a research note on Tuesday, August 22nd. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Intersect ENT has a consensus rating of “Buy” and an average price target of $27.11.

In other news, COO Richard E. Kaufman sold 12,500 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $28.25, for a total transaction of $353,125.00. Following the transaction, the chief operating officer now directly owns 169,821 shares in the company, valued at approximately $4,797,443.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $26.10, for a total transaction of $522,000.00. Following the transaction, the insider now owns 583,493 shares in the company, valued at $15,229,167.30. The disclosure for this sale can be found here. Insiders have sold a total of 133,426 shares of company stock worth $3,868,685 over the last 90 days. 13.70% of the stock is owned by company insiders.

Intersect ENT Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT, Inc. (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.